Base Year
Historical Year
Forecast Year
The global influenza vaccine market value was USD 6.33 billion in 2023, driven by increased awareness about the health risks associated with influenza across the globe. The market size is anticipated to grow at a CAGR of 7.3% during the forecast period of 2024-2032 to achieve a value of USD 11.94 billion by 2032.
An influenza vaccine, variously known as a flu vaccine, is a vaccine that provides protection against the various strains of influenza. As influenza is most prevalent in the monsoon season, the vaccine prevents the risk of influenza-related complications like ear infections and bacterial pneumonia. An influenza vaccine is one of the most crucial vaccinations to bolster the quality of life.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The increasing awareness regarding the benefits of influenza to prevent adverse side effects of influenza infection is augmenting the market growth. Various governments bodies such as the Food and Drug Administration (FDA) of the United States and the European Commission, among others, are increasingly authorising effective influenza vaccines. This, in turn, is preventing the spread of the disease and increasing the healthcare quality, hence driving the market growth. Furthermore, the growing demand for innovative zoonotic influenza vaccines to prevent the potential spread of influenza from animals is providing impetus to the growth of the market.
The market for influenza vaccine is being aided by the growing demand for influenza vaccines in developing countries due to the high prevalence of influenza-related deaths. Moreover, various governments are increasingly providing influenza vaccines for children to prevent the surge of complicated health issues. As the monsoon season in developing countries results in a surge in cases of influenza, routine administration of vaccines against the disease is recommended, which is significantly contributing to the growth of the market. In addition, the initiation of various research activities by governments to develop a vaccine that provides protection against various strains of the influenza virus is predicted to drive the market growth in the forecast period.
The market can be segmented on the basis of vaccine type, technology, route of administration, age group, distribution channel, and major region.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Vaccine Type
Market Breakup by Technology
Market Breakup by Route of Administration
Market by Age Group
Market Breakup by Distribution Channel
Market Breakup by Region
The market growth is being aided by the growing adoption of cold-adapted influenza virus vaccines to boost the efficacy and safety of vaccination. Such vaccines do not result in any adverse side effects, due to which they are increasingly preferred for children. As cold-adapted vaccines can be administered through a nasal spray, they are ideal for the trypanophobia population, which is bolstering the growth of the market. Moreover, the increasing approvals of cold-adapted influenza vaccines by healthcare bodies are driving the growth of the influenza vaccine market.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Advancements in vaccination technology are leading to the development of influenza vaccines from negative-strand RNA virus, which is predicted to propel the growth of the market. Moreover, the development of effective mRNA vaccines against SARS-CoV-2 during the COVID-19 crisis is leading to a surge in research activities to develop efficient mRNA influenza vaccines, which is expected to significantly contribute to the market growth.
In addition, various studies and clinical trials are initiated by leading companies to determine the benefits, immunogenicity, and safety of the mRNA influenza vaccine.
The report presents a detailed analysis of the following key players in the global influenza vaccine market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Vaccine Type |
|
| Breakup by Technology |
|
| Breakup by Age Group |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The influenza vaccine market was valued at USD 6.33 billion in 2023.
The market is expected to grow at a CAGR of 7.3% from 2024 to 2032 to reach a value of USD 11.94 billion by 2032.
The market is being aided by the rising awareness regarding the importance of influenza vaccines, the growing authorisation of vaccines, and the high prevalence of influenza-related issues in developing countries.
The market is expected to be propelled by the growing adoption of cold-adapted influenza vaccines, advancements in vaccines technology, and the initiation of clinical trials for the development of new and innovative influenza vaccines.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The different types of vaccine include quadrivalent and trivalent.
The technologies in the market include egg-based and cell-based, among others.
The routes of administration include injection and nasal spray.
The age groups can be categorized into paediatric and adult.
The distribution channels can be categorised into hospitals, retail pharmacies, and government suppliers, among others.
The key players in the market include AstraZeneca plc, Biodiem Limited, CSL Limited, Emergent BioSolutions Inc., Gamma Vaccines Pty Ltd, GlaxoSmithKline Plc., Merck and Co., Inc., Pfizer Inc., Sanofi S.A., and F. Hoffmann-La Roche AG.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Subscribe to our Newsletter
By subscribing you agree to with our privacy policy and provide
consent to
receive
updates
from our company.
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
Share